Oral purified bacterial extracts in acute respiratory tract infections in childhood: a systematic quantitative review by Steurer-Stey, Claudia et al.
ORIGINAL PAPER
Oral purified bacterial extracts in acute respiratory tract
infections in childhood: a systematic quantitative review
Claudia Steurer-Stey & Leonie Lagler &
Daniel A. Straub & Johann Steurer &
Lucas M. Bachmann
Received: 28 December 2005 /Revised: 1 July 2006 /Accepted: 5 July 2006 / Published online: 18 November 2006
# Springer-Verlag 2006
Abstract
Background Recurrent acute respiratory tract infections
(ARTI) are a common problem in childhood. Some
evidence suggests a benefit regarding the prevention of
ARTI in children treated with the immunomodulator OM-
85 BV (Bronchovaxom).
Methods We summarised the evidence on the effectiveness
of the immunomodulator OM-85 BV in the prevention of
ARTI in children. We searched randomised comparisons of
oral purified bacterial extracts against inactive controls in
children with respiratory tract diseases in nine electronic
databases and reference lists of included studies. We
extracted salient features of each study, calculated relative
risks (RR) or weighted mean differences (WMD) and
performed meta-analyses using random-effects models.
Results Thirteen studies (2,721 patients) of low to moderate
quality tested OM-85 BV. Patients and outcomes differed
substantially, which impeded pooling results of more than
two trials. Two studies (240 patients) reporting on the
number of patients with less than three infections over 6
month of follow-up in children not in day care showed a
trend for benefit RR 0.82 (95% CI, 0.65–1.02). One out of
two studies examining the number of children not in day
care without infections over 4–6 month reported a
significant RR of 0.42 (95% CI, 0.21–0.82) whereas the
smaller, second study did not [RR 0.92 (95% CI, 0.58–
1.46)]. Two studies reporting the number of antibiotic
courses indicated a benefit for the intervention arm [WMD
2.0 (95% CI, 1.7–2.3)]. Two out of the three studies showed
a reduction of length of episodes of 4–6 days whereas a
third study showed no difference between the two groups.
Conclusion Evidence in favour of OM-85 BV in the
prevention of ARTI in children is weak. There is a trend
for fewer and shorter infections and a reduction of
antibiotic use.
Keywords Bronchovaxom . Immunotherapy .
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Background
Recurrent acute respiratory tract infections (ARTI) are a
common problem in childhood [2]. The majority of acute
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airway tract infections are caused by viruses. However,
several bacterial complications can appear, such as acute
otitis media, sinusitis and bronchitis. Therefore, physicians
are prone to prescribe antibiotics to treat ARTI although
only a small proportion of children will benefit from this
treatment. Due to this over-prescription, many bacteria have
become resistant against commonly prescribed antibiotics.
To overcome this treatment dilemma, several authors
proposed changing the treatment strategy of ARTI from
acute intervention to prophylaxis of recurrence using
vaccines and immunomodulating agents [10]. Defects in
the immunological system, such as selective immunoglob-
ulin A (IgA) deficiency, are known to be linked with
frequent respiratory infections by bacteria and viruses.
From an epidemiologic point of view, it has been shown
that over 50% of children with three or more episodes a
year during at least 2 years were deficient in one of the IgG
subclasses and that 17% were IgA deficient [4].
OM-85 BV (Bronchovaxom, OM Pharma, Geneva
Switzerland), an orally administered immunostimulator
(capsules of 3.5 mg) containing lyophilised bacterial
fractions of Haemophilus influenzae, Diplococcus pneumo-
niae, Klebsiella pneumoniae and K. ozaenae, Staphylococ-
cus aureus, Streptococcus pyogenes and S. viridans and
Moraxella catarrhalis, provokes a local immune response
via activation of the mucosa-associated lymphoid tissue and
stimulates the production of salivary and bronchoalveolar
serum IgA as well as serum IgA and IgG. It has been
widely used in several European countries in children and
adults assuming it will prevent recurrences of respiratory
tract infections (RTIs). In adult patients with chronic
bronchitis and chronic obstructive pulmonary disease
(COPD), a systematic review could not find a preventive
effect on exacerbations [22]. Recent clinical studies in
children reported on significantly reduced rates of RTIs
with good safety and tolerance [9, 18]. Up to now, however,
the literature has not been assembled and appraised but is
scattered and not easy to access. Furthermore, results from
these studies are imprecise. We therefore performed a
systematic review to investigate the efficacy and harm of
these immunostimulating drugs in the prophylaxis of ARTI
in children.
Methods
Our review was based on a prospective protocol using
widely recommended methodology [1, 7].
Data sources
We searched in Medline, Premedline, EMBASE, Lilacs,
Biosis, CINAHL, HealthStar, Inspec and the Cochrane
Controlled Trials Register without language restriction
using combinations of the terms OM-85 BV, Broncho-
vaxom, Luivac bacterial and lysate immunotherapy, respi-
ratory tract disease. Searches were limited to “human”. The
last electronic search was in April 2005. Searches were
complemented by screening reference lists of included
reports and of relevant review articles, contacting authors of
included reports and contacting two manufacturers of
bacterial lysates: OM Pharma, Switzerland, and Sankyo
Pharma, Switzerland, for additional trials and unpublished
data.
Study selection
Reports were considered if they described randomised
controlled trials of an oral bacterial extract (active)
compared with an inactive control (placebo or no treatment)
in children with respiratory tract diseases. Relevant studies
had to report on clinical endpoints of efficacy or harm.
Studies on immunological parameters were not considered.
There was the intention to consider data from abstracts of
scientific meetings if the study methods were clearly
described and data reporting was adequate.
Validity assessment
One author (CS) screened all retrieved reports. Three
authors (LL, CS, LMB,) assessed the selected studies for
methodological quality using components of study design
that would ensure internal validity [1]. Information was
sought for the adequacy of patient enrolment, sequence
generation, concealment of allocation, blinding (patient,
caregiver, outcome assessment, data analysis), a statement
on how dropouts were handled and details to enable
intention-to-treat analysis (maximum score 6 points). We
sought information on these aspects because random
allocation of subjects (with concealment of allocation
sequence) prevents selection bias and ensures that compar-
ison groups are balanced on average for known, unknown
and unmeasured confounding variables [19, 20]. Blinding
statisticians to group allocation was used, as it prevents bias
in analysis. An intention-to-treat analysis is important in
preventing attrition bias by considering data for all patients,
including those who dropped out. Discrepancies were
resolved by discussion.
Data extraction
Information about bacterial lysate regimens (drug, dose,
route of administration, duration of treatment), number of
patients enrolled and analysed, length of follow-up, and
outcome measures were entered in standard collection
sheets. Particular attention was given to specifying whether
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children attended day schools since previous studies
identified an increased risk for upper respiratory infections
in those children. This was done by one investigator (LL)
and cross-checked by two others (LMB, CS). The primary
outcome measure was prevention of ARTI. An upper ARTI
was defined as the presence of at least one of the following
signs: rhinorrhea, sore throat or cough. Lower ARTI was
defined as the presence of at least one of the following
signs: rales or crepitations, wheezing, pathologic respiratory
rate or stridor. If not defined in detail in the original study,
information about infections was taken as reported in the
original trials. Secondary outcome measures were symptom
duration and improvement as assessed by the observers and
the patients, rate of hospitalisation due to infections,
reduction of antibiotic requirements, school absences and
adverse effects.
Analysis
From each study, outcome data and data on harm were
abstracted into 2×2 tables. Heterogeneity (i.e. differences
between studies) of risk ratios was assessed graphically
using forest plots and statistically using the chi-squared test
to aid in decisions on how to proceed with quantitative
synthesis. This formal statistical analysis examined whether
the observed variation in study results was compatible with
the variation expected by chance alone. Exploration of the
causes of heterogeneity was planned using variation in
features of the population (inclusion and exclusion criteria)
intervention (drug regimens) and study outcome and
quality. If appropriate, we planned to perform meta-analysis
where relative risks from individual studies would be
pooled using a fixed effects model if no heterogeneity
was detected. In case of heterogeneity, we decided to pool
using a random effects model [5]. Results are presented as
weighted mean differences (WMD), relative risks (RR) and
corresponding 95% confidence intervals. Statistical analy-
Fig. 1 Study selection process
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ses were carried out using the STATA software package
(Stata Corp. 2005, Stata Statistical Software: Release 8.2
College Station, TX, USA).
Results
Our searches identified 520 references out of which 465
were subsequently excluded after screening of titles and
abstracts (where available). Full texts of the remaining 55
articles were obtained and evaluated for inclusion in the
review. Ultimately, 13 studies including 2,721 patients
fulfilled our inclusion criteria. (For details, see Fig. 1)
Nine studies [3, 6, 9, 11, 13, 15, 18, 21, 23] were
published in English, two [16, 17] in German, one [14] in
French and one [8] in Spanish. There was a large variety in
reported endpoints. Four trials [9, 11, 18, 21] reported on
absences from school, nine [3, 6, 8, 9, 11, 16, 17, 21, 23] on
the number of ARTIs during the study and seven [8, 9, 11,
16, 17, 21, 23] on infection duration. Seven (53.9%) [8, 9,
11, 15–17, 23] reported the number of antibiotic courses.
Only two trials [8, 23] reported about the improvement of
symptoms, and no study reported hospitalisation rate due to
infections.
Methodological quality
All trials were placebo controlled; there were no head-to-
head comparisons. In general, methodological quality was
poor to moderate (Table 1). The median score was 2.69; no
trial scored 6 and only three trials scored 5 [6, 9, 18]
(Table 2). Five studies [6, 9, 11, 16, 18] reported on
consecutive patient enrolment, and four [3, 6, 9, 18]
reported on details of generation of random sequence and
concealment of treatment allocation. All studies but one
[21] included a statement on how they dealt with dropouts
and were using an intention-to-treat analysis. Only four
studies [6, 9, 11, 18], however, provided details about
Table 1 Results of quality assessment
Study/year Consecutive patient
enrolment
Description of
generation of
random sequence
Description of
concealment of
randomisation
Blinding Statement
on how
dropouts
were handled
Intention-
to-treat
analysis
Score
Gutierrez
2001 [9]
Yes Yes Not reported Yes Yes Yes 5
Schaad 2002
[18]
Yes Yes Not reported Yes Yes Yes 5
Del-Rio-
Navarro
2003 [6]
Yes Yes Not reported Yes Yes Yes 5
Jara-Perez
2000 [11]
Yes Not reported Not reported Yes Yes Yes 4
Collet 1993
[3]
Not reported Yes Not reported Not reported Yes Yes 3
Martin du
Pan 1982
[14]
Not reported Not reported Not reported Not reported Yes Yes 2
Maestroni
1984 [13]
Not reported Not reported Not reported Not reported Yes Yes 2
Schaad 1986
[17]
Not reported Not reported Not reported Not reported Yes Yes 2
Zagar 1988
[23]
Not reported Not reported Not reported Not reported Yes Yes 2
Paupe 1991
[15]
Not reported Not reported Not reported Not reported Yes Yes 2
Riedl-Seifert
1993 [16]
Yes Not reported Not reported Not reported Yes Yes 2
Gomez 1998
[8]
Not reported Not reported Not reported Yes Not reported 1
Sramek
1986 [21]
Not reported Not reported Not reported Not reported Not reported Not
reported
0
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blinding of patients and caregivers. Ten trials (76.92%) [3,
6, 8, 9, 11, 14, 15, 18, 21, 23] acknowledged sponsorship
by a manufacturer; in one study [8], one author was
collaborator of a manufacturer.
Patients
Nine trials reported on demographic data [3, 6, 8, 9, 11, 15–
18, 23]; there were more females than males (767 females
vs. 700 males). Inclusion criteria were three or more
infections in the previous 6 months in six trials [6, 9, 11,
Fig. 2 a Children not in day care. Number of patients with less than
three infections over 6 months of follow-up: In Maestroni (1984),
more patients in the OM-85 BV group had less than three infections
than patients treated in the placebo group. In Schaad (2002), pooled
results (random effects) show a favourable effect in the active group. b
Patients not in day care. Number of patients without infections over 4–
6 month: In one study, Paupe (1991), the relative risk to have
infections over 4–6 months was significantly reduced. The second
smaller study, Martin du Pan (1982), showed no beneficial effect.
Pooling these two studies using a random-effects model resulted in a
non-significant effect of OM-85 BV
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15, 16, 18]; no anatomic alterations of the respiratory tract
in four [6, 8, 9, 11]; no treatment with corticosteroids,
immunostimulants or immunosuppressants in eight [3, 6, 9,
11, 15–18] and no chronic respiratory disease, autoimmune
diseases or liver or kidney failure in five [6, 8, 9, 11, 18]
(Table 2).
Efficacy endpoints
Although several studies reported on the same outcome
category, variation in outcome parameter (e.g. less than six
infections vs. less than three infections) impeded combining
results of more than two trials. Two studies (240 patients)
reported on the number of patients with less than three
infections over 6 months of follow-up in children not in day
care [13, 18]. The two studies showed a trend for benefit
(RR 0.82; 95% CI 0.65–1.02) (Fig. 2a). Two studies
reported on the number of patients without infections over
4–6 months in children not in day care. In one study, the
number of infections over 4–6 months was significantly
reduced (RR 0.42; 95% CI 0.21–0.82) [15]. The other
smaller study did not show a beneficial effect (RR 0.92;
95% CI 0.58–1.46) [14] (pooled RR using a random-effects
model 0.64 (95%CI 0.26–1.57) (Fig. 2b).
Three studies [8, 17, 23] reported on duration of
episodes. Two out of the three showed a reduction of 4–
6 days whereas one study showed no difference between
the two groups (Fig. 3). Finally, two studies [9, 11]
reporting on the number of antibiotic courses indicated a
benefit for the intervention arm [WMD 2.0 (95% CI, 1.7–
2.3)]. (For the complete list of assessed endpoints, see
Table 1.)
Adverse events
Nine studies reported on gastrointestinal, urinary tract, skin
and allergic adverse effects [3, 6, 9, 11, 15–18, 23]. Paupe
[15] reported diarrhoea in one patient in the active group
and two patients in the control group. In the study of
Schaad [18], adverse reactions in the OM-85 group were
diarrhoea (two patients), abdominal pain (two patients),
fatigue, urinary frequency (twice in the same patient) and
exanthema. In the placebo group, there was one allergic
reaction. In Schaad [17], there was one case of urticaria in
the control group; no adverse event was reported in the
Bronchovaxom group. Collet [3] recorded 17 medical
events for the treated group and 19 for the placebo group.
The adverse effects were very infrequent and appeared
unlikely to be related with the study medication. Del Rio
Navarro [6] recorded eight patients in the active group with
ten adverse events; only three were related to drug
administration: gastroenteritis, gastroenteritis with melena
and diarrhoea. Nine patients taking placebos had ten
adverse effects; four were related to the administration of
the placebo: gastritis, diarrhoea (trial withdrawal), vomit
and asthma. Riedl-Seifert [16] recorded eight patients in the
active group with gastrointestinal symptoms: three with
skin problems and one with other side effects. In the
placebo group were five patients with gastrointestinal
manifestations and one patient with skin problems. Jara
Perez [11] and Zagar [23] reported that there were no
adverse effects.
Fig. 3 Duration of episodes (days): Zagar (1988) and Gomez-Barreto
(1998) showed that in the group treated with OM-85 BV, the duration
of episodes was shorter than in the control group (Zagar: 6 days
shorter; Gomez: 4 days shorter). In Schaad’s study (1986), the
duration of episodes was shorter in the control group (2 days). (We
refrained from pooling the results of these strongly heterogeneous
studies.)
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Discussion
Our systematic review provides weak evidence that oral
immunostimulation with bacterial extracts prevents ARTIs
in children. There was a trend for fewer infections over 6
months of follow-up in children not in day care and a small
reduction in number of antibiotic courses. Safety and
tolerance of Bronchovaxom were good.
What are the limitations of this review? We think that
searches and selection procedures were adequate. However,
some important limitations of our review are related to the
limited validity of the original trials. The overall quality of
the trials was moderate to poor. While, for example, the
included trials reported on clinically homogenous settings,
treatment regimens and similar follow-up periods, impor-
tant methodological items such as patient enrolment,
generation of random sequence, concealment of treatment
allocation and details about statistical analyses were seldom
reported. Furthermore, most trials were of limited size. The
problem with small trials is that they may generate
treatment effects by random chance. Pharmaceutical com-
panies sponsored ten of the trials; in one study, a co-author
was working for the manufacturer. An association between
competing interests and authors’ conclusions has been
shown [12]. In our meta-analysis, however, authors’
conclusions per se were not considered. We do not know
how potential competing interests may influence the way a
clinical trial is designed and conducted or the way data are
analysed and reported. The trials reported on a large variety
of different endpoints. It was impossible to compare
outcome data from more than three trials. Although the
main endpoint, reduction of the number of infections, was
reported in nine trials, differences in outcome definition (e.g.
less than six vs. less than three infections) allowed
combining the results of two trials only. Finally, data were
too sparse to allow formal sensitivity analyses, addressing,
for instance, the impact of treatment duration.
What are the implications for research? We think that
further studies should examine which children benefit
most. For example, otherwise healthy children reporting
more than five ARTIs per six months before study
inclusion could be studied. Furthermore, infants with
chronic lung diseases or immunocompromised children
should be enrolled because these populations are at very
high risk for severe morbidity and have higher risk for
mortality.
Conclusions
Evidence in favour of Bronchovaxom in the prevention of
ARTIs in children is weak. There is a trend for fewer and
shorter infections and a reduction of antibiotic use.
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